RxDoctor Payments Data

April Shaw, PA

Medical · San Antonio, TXNPI 1609427194

Payments from drug & device makers

$1,287in general payments, 2019–2025

Across 34 payments — averaging $37.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$501
  • Novo Nordisk$358
  • Lilly USA, LLC$180
  • Ultragenyx Pharmaceutical Inc.$41
  • Novartis$32
  • Althera Pharmaceuticals LLC$29
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$1,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,287 in reported general payments places this provider in the 60th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$3,983
Medicare patients
48
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$19,632
JardianceEmpagliflozin23$14,898
Tresiba Flextouch U-100Insulin Degludec12$6,140
Wixela InhubFluticasone Propion/Salmeterol12$2,185
Novolog FlexpenInsulin Aspart13$1,929
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,275
SynthroidLevothyroxine Sodium14$779
Albuterol Sulfate HfaAlbuterol Sulfate16$561
Omeprazole43$500
Metoprolol Succinate36$489
Atorvastatin Calcium60$390
Diltiazem 24hr ErDiltiazem Hcl12$370
Famotidine20$329
Losartan Potassium51$290
Potassium Chloride20$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$358$19,63220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,490 medical providers in Texas.

Other medical in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →